FDA clears CathEffects' mapping system:
This article was originally published in Clinica
Executive Summary
CathEffects has received US clearance to market its cardiac electrophysiology mapping system for use with its previously FDA-cleared five-electrode two-plane mapping catheter (see Clinica No 978, p 17). The Desai VectorCath mapping system offers an economic product that reduces mapping time and improves accuracy," said Shawn Fojtik, the firm's COO. "The mapping system is inexpensive when compared to other systems, requires almost no procedure set-up time, and delivers instantaneous mapping data," Mr Fojtik added.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.